Weaning From High Flow Nasal Oxygen in Acute Respiratory Failure : a Target Trial Emulation

Condition(s) studied

Study summary

Acute respiratory failure is a frequent reason for admission to the intensive care unit (ICU). It is associated with high healthcare consumption and mortality.

High-flow nasal oxygen (HFNO) improves comfort, reduces the risk of intubation and may reduce the risk of mortality in the most severe patients with acute hypoxemic respiratory failure compared with other oxygenation strategies. Therefore, HFNO is recommended as a first-line non-invasive oxygenation strategy in acute hypoxemic respiratory failure.

The timing of weaning patients from HFNO is complex. On the one hand, failure to wean from HFNO is associated with prolonged duration of HFNO and prolonged ICU stay. On the other hand, continued HFNO in patients ready to be weaned may unnecessarily prolong ICU stay and contribute to overwhelming of ICU capacities.

The overarching goal of this study is to identify the characteristics of patients in whom weaning from HFNO is not beneficial.

Eligibility

Primary outcome measure(s)

• Hospital-free days at day 90 — 90 days
  The number of days alive out of hospital between pseudorandomization and D90. For patients who died, the hospital-free days at day 90 will be equal to 0.

Trial sites (3)

More Poitiers University Hospital trials in France

Other trials for the same condition